Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...

Tooth enamel is the hardest substance in the human body, yet once damaged, it cannot regenerate naturally. To overcome this ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

InxMed Co., Ltd ('InxMed'), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical ...

STEMCELL Technologies et le Centre for Commercialization of Regenerative Medicine (CCRM) ont annoncé aujourd’hui un ...

Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to ...

FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics ...

After decades of failed HIV vaccines, a new approach that predicts which cells to train, not just what antigen to show, has ...

A new genetic screening method allows researchers to efficiently modulate individual genes across entire tissues and provides ...